{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:12:56Z","timestamp":1767978776829,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.thromres.2018.09.044","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T14:23:32Z","timestamp":1536157412000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7225-8228","authenticated-orcid":false,"given":"Meera","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara A.","family":"Fylling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneel A.","family":"Ashrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela L.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Christopher","family":"Hook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laynalee K.","family":"Cardel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv K.","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2018.09.044_bb0005","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11239-010-0529-6","article-title":"Acquired factor V inhibitors: a systematic review","volume":"31","author":"Franchini","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"issue":"1","key":"10.1016\/j.thromres.2018.09.044_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00000658-200101000-00014","article-title":"Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin","volume":"233","author":"Ortel","year":"2001","journal-title":"Ann. Surg."},{"issue":"4","key":"10.1016\/j.thromres.2018.09.044_bb0015","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0022-2143(99)90062-8","article-title":"Clinical and laboratory manifestations of anti-factor V antibodies","volume":"133","author":"Ortel","year":"1999","journal-title":"J. Lab. Clin. Med."},{"issue":"1","key":"10.1016\/j.thromres.2018.09.044_bb0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0038-1657130","article-title":"A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay","volume":"47","author":"Austen","year":"1982","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2018.09.044_bb0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00062752-199909000-00008","article-title":"Autoimmune factor VIII inhibitors","volume":"6","author":"Pruthi","year":"1999","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.thromres.2018.09.044_bb0030","series-title":"Continuing Education Program Sample No. TH81-2","article-title":"Inhibitor of factor VIII coagulant activity","author":"Bowie","year":"1981"},{"key":"10.1016\/j.thromres.2018.09.044_bb0035","series-title":"The Diagnosis of Bleeding Disorders","first-page":"85","article-title":"Tests of hemostasis and blood coagulation","year":"1975"},{"issue":"1","key":"10.1016\/j.thromres.2018.09.044_bb0040","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/hae.12066","article-title":"Successful treatment with thalidomide of a patient with congenital factor V deficiency and factor V inhibitor with recurrent gastrointestinal bleeding from small bowel arteriovenous malformations","volume":"19","author":"Perez Botero","year":"2013","journal-title":"Haemophilia"},{"issue":"12","key":"10.1016\/j.thromres.2018.09.044_bb0045","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.5858\/arpa.2016-0445-RS","article-title":"Factor V inhibitors: a diagnostic and therapeutic challenge","volume":"141","author":"Olson","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"4","key":"10.1016\/j.thromres.2018.09.044_bb0050","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1076029606293438","article-title":"Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases","volume":"12","author":"Wiwanitkit","year":"2006","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2018.09.044_bb0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1172\/JCI112318","article-title":"Isolation and study of an acquired inhibitor of human coagulation factor V","volume":"77","author":"Nesheim","year":"1986","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.thromres.2018.09.044_bb0060","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1182\/blood.V91.11.4188","article-title":"Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations","volume":"91","author":"Ortel","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2018.09.044_bb0065","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood.V76.10.2011.2011","article-title":"Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin","volume":"76","author":"Zehnder","year":"1990","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2018.09.044_bb0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0049-3848(95)90865-D","article-title":"Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid","volume":"77","author":"Suehisa","year":"1995","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2018.09.044_bb0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0950-3536(98)80050-4","article-title":"Acquired factor V inhibitors","volume":"11","author":"Knobl","year":"1998","journal-title":"Baillieres Clin. Haematol."},{"issue":"12","key":"10.1016\/j.thromres.2018.09.044_bb0080","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V77.12.2637.2637","article-title":"Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality","volume":"77","author":"Gastineau","year":"1991","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2018.09.044_bb0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2141.2000.02183.x","article-title":"Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis","volume":"110","author":"Mumford","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2018.09.044_bb0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MBC.0000000000000600","article-title":"Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis","volume":"28","author":"Harrison","year":"2017","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"6","key":"10.1016\/j.thromres.2018.09.044_bb0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00001721-200209000-00011","article-title":"Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis","volume":"13","author":"Emori","year":"2002","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"1","key":"10.1016\/j.thromres.2018.09.044_bb0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1537-2995.2002.00011.x","article-title":"Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure","volume":"42","author":"Streiff","year":"2002","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.thromres.2018.09.044_bb0105","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V56.5.835.835","article-title":"Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions","volume":"56","author":"Chediak","year":"1980","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2018.09.044_bb0110","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/00043426-199705000-00009","article-title":"Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin","volume":"19","author":"Tarantino","year":"1997","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2018.09.044_bb0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.20181","article-title":"Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis","volume":"77","author":"Lian","year":"2004","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2018.09.044_bb0120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/(SICI)1096-8652(199604)51:4<315::AID-AJH11>3.0.CO;2-D","article-title":"Multimodality therapy of an acquired factor V inhibitor","volume":"51","author":"Fu","year":"1996","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.thromres.2018.09.044_bb0125","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4065\/82.7.864","article-title":"How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults","volume":"82","author":"Kamal","year":"2007","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.thromres.2018.09.044_bb0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1160\/TH07-07-0448","article-title":"Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature","volume":"99","author":"Zurcher","year":"2008","journal-title":"Thromb. Haemost."},{"issue":"1\u20132","key":"10.1016\/j.thromres.2018.09.044_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cca.2008.05.003","article-title":"Laboratory, clinical and therapeutic aspects of acquired hemophilia A","volume":"395","author":"Franchini","year":"2008","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.thromres.2018.09.044_bb0140","first-page":"224","article-title":"A spontaneous factor V inhibitor with unexpected laboratory features","volume":"110","author":"Brandt","year":"1986","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"2","key":"10.1016\/j.thromres.2018.09.044_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818305280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818305280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T15:08:35Z","timestamp":1571843315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818305280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":29,"alternative-id":["S0049384818305280"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.09.044","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and laboratory diagnosis of autoimmune factor V inhibitors: A single institutional experience","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}